(S)-2-(3,4-dichlorophenyl)pent-4-enoyl chloride | 156300-02-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-(3,4-dichlorophenyl)pent-4-enoyl chloride
• 英文别名: (S)-2-(3,4-dichlorophenyl)pent-4-enol chloride；(2S)-2-(3,4-dichlorophenyl)pent-4-enoyl chloride
• CAS: 156300-02-6
• 化学式: C₁₁H₉Cl₃O
• 分子量: 263.551
• InChiKey: DANBHKIZEZOVDV-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (S)-2-(3,4-dichlorophenyl)pent-4-enoyl chloride 在 ammonium hydroxide 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 2(S)-(3,4-dichlorophenyl)-4-pentenamine
  参考文献：
  名称：

  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure–activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes

  摘要：

  Screening of the Merck sample collection for compounds with CCR5 receptor binding afforded (2S)-2-(3,4-dichlorophenyl)- 1-[N-(methyl)-N-(phenylsulfonyl)amino]-4,4'-piperidin-1'-yl)]butane S-oxide (4) as a potent lead structure having an IC50 binding affinity of 35 nM. Herein, we describe the discovery of this lead structure and our initial structure-activity relationship studies directed toward the requirement for and optimization of the 1-amino fragment. (C) 2001 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(00)00637-5
• 作为产物：
  描述：

  2-(3,4-dichlorophenyl)-pent-4-enoic acid 在 草酰氯 、 (S)-(-)- α-甲基苄胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-2-(3,4-dichlorophenyl)pent-4-enoyl chloride
  参考文献：
  名称：

  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure–activity relationships for substituted 2-aryl-1-[ N -(methyl)- N -(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes

  摘要：

  (2S)-2-(3,4-二氯苯基)-1-[N-(甲基)-N-(苯基亚砜)氨基]-4-[螺(2,3-二氢苯并噻吩-3,4'-哌啶-1'-基)]丁烷 S-氧化物 (3) 已被鉴定为一种具有强效 CCR5 拮抗活性的先导结构化合物，其 IC50 值为 35 nM。本文中，我们描述了针对 C-2 苯基片段的需求和优化的结构-活性关系研究。研究发现，苯基对于 CCR5 拮抗活性至关重要，取代基仅限于在 3 位引入小型基团（如 13 和 16，当 X=H、3-F、3-Cl、3-Me 时）。(C) 2001 Elsevier Science Ltd. 出版。

  DOI：

  10.1016/s0960-894x(00)00639-9

文献信息

• Carboxy substituted acylic carboxamide derivatives
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06316445B1

  公开（公告）日：2001-11-13

  The present invention relates to novel carboxy substituted acyclic carboxamide derivatives of formula (1)): and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, cough, and bronchitis.

  本发明涉及新型的带有羧基取代的无环羧酰胺衍生物（化学式（1））及其立体异构体和药学上可接受的盐，以及它们作为速激肽受体拮抗剂的用途。这类拮抗剂在治疗包括哮喘、咳嗽和支气管炎在内的速激肽介导的疾病和症状中很有用。
• Aryl and biaryl compounds having MCH modulatory activity
  申请人：SCHERING CORPORATION

  公开号：US20030092715A1

  公开（公告）日：2003-05-15

  In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration or one or more of diseases associated with the MCH receptor. An illustrative inventive compound is shown below: 1

  本发明的其中一个实施例提供了一类新颖的化合物，作为MCH受体的拮抗剂，制备这类化合物的方法，包含一个或多个此类化合物的药物组合物，制备包含一个或多个此类化合物的药物制剂的方法，以及治疗、预防或改善与MCH受体相关的一个或多个疾病的方法。下面展示了一个说明性的创新化合物：1
• [EN] ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY<br/>[FR] COMPOSES D'ARYLE ET DE BIARYLE AYANT UNE ACTIVITE MODULATRICE DE MCH
  申请人：PHARMACOPEIA INC

  公开号：WO2002076929A1

  公开（公告）日：2002-10-03

  In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration or one or more of diseases associated with the MCH receptor. An illustrative inventive compound is shown here.

  在一种实施方式中，本发明提供了一类新型化合物作为MCH受体拮抗剂，制备这种化合物的方法，含有一种或多种这种化合物的药物组合物，制备包含一种或多种这种化合物的药物配方的方法，以及治疗、预防或改善与MCH受体相关的一种或多种疾病的方法。这里展示了一种有创造性的化合物。
• CARBOXY SUBSTITUTED CARBOXAMIDE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1077942B1

  公开（公告）日：2005-01-12
• Addition of Transiently-Generated Methyl <i>o</i>-Lithiobenzoate to Imines. An Isoindolone Annulation
  作者：James B. Campbell、Robert F. Dedinas、Sally A. Trumbower-Walsh

  DOI：10.1021/jo960582w

  日期：1996.1.1

  Addition of phenyllithium to a mixture of an imine, methyl o-iodobenzoate, and BF3 . etherate at -105 degrees C gives good to excellent yields of isoindolones. The transient formation of methyl o-lithiobenzoate is proposed, which is formed by a rapid lithium/iodide exchange reaction of the phenyllithium with methyl o-iodobenzoate in the presence of the imine. The transiently generated anions can then be captured by the BF3-activated imines to form the isoindolones in good to high yield. The reactions conditions are sufficiently mild, and selective, to permit functional groups such carbmethoxy and aryl bromide, which could otherwise react with the added PhLi, to be tolerated.